Full Press Release Details
Canopy Growth Reports Third Quarter Fiscal
2020 Financial Results
Generated $124 million
Net Revenue, up from $76 million in Q2 2020
Excluding portfolio restructuring charges in Q2 2020, Net Revenue up 13%
Achieved Gross Margin of 34%
Total Operating Expenses down 14% versus the prior quarter
Adjusted EBITDA loss decreases to $92 million
SMITHS FALLS, ON, Feb. 14, 2020 /CNW/ - Canopy
Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE: CGC) today announced its financial
results for the third quarter ended December 31, 2019. All financial information in this press release is reported in millions
of Canadian dollars, unless otherwise indicated.
| Third Quarter Fiscal 2020 Financial Summary | |||||
| Gross revenue 1 | Net revenue | Gross margin 2 | Adjusted EBITDA 3 | Free cash flow 4 | |
| Reported | $135.6 | $123.8 | 34% | $(91.7) | $(359.6) |
| % change vs. Q2 2020 | 15% | 62% | NM | 41% | 16% |
| % change vs. Q3 2019 | 39% | 49% | 800 bps | -23% | -20% |
| 1 Excludes the impact of other revenue adjustments in Q2 2020, which represent the Company's determination of returns and pricing adjustments. |
| 2 Gross margin is before fair value impacts in cost of sale, and is a non-IFRS measure. See "Non-IFRS Measures" below. |
| 3 Adjusted EBITDA is a non-IFRS measure. See "Non-IFRS Measures" below. |
| 4 Free cash flow is defined as operating cash flow less capital expenditures, and is a non-IFRS measure. See "Non-IFRS Measures" below. |
Third Quarter Fiscal 2020 Corporate Financial
Revenues: Reported Net Revenues increased 62% over
Q2 2020, or 13% excluding the impact of portfolio restructuring charges. Gross Recreational B2B revenue increased 8% over prior
quarter due, in part, to over 140 stores becoming active in the quarter and higher sales of premium dried flower and pre-roll joints.
Our acquired businesses including Storz & Bickel and This Works also performed well, contributing to organic growth this quarter.
Gross margin: Gross margin before fair value impacts
was 34%. Gross margin performance in quarter benefited from lower period costs due to higher facility utilization
Operating expenses: Total operating expenses decreased
14% versus Q2 2020 primarily due to a $20 million reduction in G&A expenses and over $31 million lower stock-based compensation
versus the prior quarter
Adjusted EBITDA: Adjusted EBITDA loss of $92 million,
a $64 million narrower loss versus Q2 2020 driven by higher sales, improved gross margins and lower operating expenses
Cash Position: Gross cash balance was $2.3 billion,
down from $2.7 billion in Q2 2020, reflecting the EBITDA loss, capital investments and M&A
Third Quarter Fiscal 2020 Business &
Operational Highlights
Maintained leading market share in retail, at an estimated
22%, of the Canadian recreation market as we saw a strong demand for both premium and value priced dried flower and pre-rolled
Continued market share gains and increase in the number
of patients, to over 76,700, in the Canadian medical cannabis market
Named David Klein as new Chief Executive Officer
Completed first shipments of cannabis-infused edible chocolates
and JUJU Power 510 batteries in December 2019
Storz & Bickel expanded product line with launch of
Crafty+ vaporizer in November 2019
Announced initial line of First & Free Hemp-derived
CBD products and began sales online through www.firstandfree.com, one quarter ahead of Q4 2020 target
"In Q3 we executed across Canada, in our
international markets and in our strategic acquisitions to drive revenue growth," said David Klein, CEO. "We have a lot
of work to do. We are eager to capitalize on the opportunity to create an unassailable position through a tight focus on
the consumer and on critical markets."
"We delivered significant gross improvement
in the third quarter driven by stronger revenues and higher capacity utilization. Actions taken earlier this year are expected
to meaningfully reduce stock-based compensation in FY21, and we have started to implement tighter cost controls across the organization,"
said Mike Lee, EVP & CFO. "We plan to take further steps to reduce our costs and right-size our business to ensure that
we can generate a healthy margin profile and cash generation in the coming years."
| Third Quarter Fiscal 2020 Financial and Operational Review | |||||
| Q3 2020 | Q2 2020 | % Change | Q3 2019 | % Change | |
| Canadian recreational cannabis | |||||
| - Business to business 1 | $53.5 | $49.4 | 8% | $60.1 | -11% |
| - Business to consumer | $15.2 | $13.1 | 16% | $11.5 | 32% |
| Canadian medical cannabis | $14.8 | $14.1 | 5% | $15.9 | -7% |
| Canadian cannabis | $83.5 | $76.6 | 9% | $87.5 | -5% |
| International medical cannabis | $18.7 | $18.1 | 3% | $2.7 | 593% |
| Cannabis gross revenue excluding other revenue adjustments | $102.2 | $94.7 | 8% | $90.2 | 13% |
| Other revenue | $33.4 | $23.6 | 42% | $7.5 | 345% |
| Gross revenue excluding other revenue adjustments | $135.6 | $118.3 | 15% | $97.7 | 39% |
| Other revenue adjustments 2 | $- | $32.7 | -100% | $- | NM |
| Excise taxes 3 | $11.8 | $9.0 | 31% | $14.7 | -20% |
| Net revenue | $123.8 | $76.6 | 62% | $83.0 | 49% |
| 1 Excludes the impact of other revenue adjustments. |
| 2 Other revenue adjustments represent the Company's determination of returns and pricing adjustments. |
| 3 Excise taxes is presented net of the impact from other revenue adjustments. |
Recreational B2B sales increased 8% over Q2 2020, due to
over 140 stores becoming active in the quarter and higher sales of premium dried flower and pre-roll joints
Recreational B2C sales increased 16% over prior quarter,
due in part to an 11% increase in same store sales
Medical sales increased 5% over the prior quarter primarily
attributable to the broadening of our brand and product offerings, including the availability of products from additional CraftGrow
partners, as well as an increase in number of customers to over 76,700.
International Cannabis
C3 revenue increased 5% over Q2 2020
Germany cannabis sales higher than expected due to opportunistic
sales into the German market to fill a supply gap that resulted from a regulatory enforced sales halt of cannabis products offered
Strategic Acquisitions
Storz & Bickel vaporizer revenue increased 46% over
Q2 2020 due to solid organic growth and seasonal sales
This Works revenue increased 42% over prior quarter due
to strong organic growth
| Third Quarter Fiscal 2020 Cannabis Product Revenue Highlights | |||||||
| Q3 2020 | Q2 2020 | % Change | Q3 2019 | % Change | |||
| Canadian recreational - Business to business | |||||||
| Dry cannabis | $55.8 | $47.4 | 18% | $39.3 | 42% | ||
| Cannabis oil and softgels excluding other revenue adjustments | $3.0 | $2.0 | 50% | $20.8 | -86% | ||
| Other revenue adjustments 1 | $(5.3) | $(32.7) | -84% | $- | NM | ||
| $53.5 | $16.7 | 220% | $60.1 | -11% | |||
| Canadian recreational - Business to consumer | |||||||
| Dry cannabis | $13.5 | $11.6 | 16% | $10.9 | 24% | ||
| Cannabis oil and softgels | $1.7 | $1.5 | 13% | $0.6 | 183% | ||
| $15.2 | $13.1 | 16% | $11.5 | 32% | |||
| Canadian medical | |||||||
| Dry cannabis | $5.3 | $5.5 | -4% | $8.1 | -35% | ||
| Cannabis oil and softgels | $9.5 | $8.6 | 10% | $7.8 | 22% | ||
| $14.8 | $14.1 | 5% | $15.9 | -7% | |||
| International medical | |||||||
| Dry cannabis | $3.9 | $4.1 | -5% | $2.7 | 44% | ||
| Cannabis oil and softgels | $14.8 | $14.0 | 6% | $- | NM | ||
| $18.7 | $18.1 | 3% | $2.7 | 593% |
| Third Quarter Fiscal 2020 Adjusted EBITDA | |||||
| Q3 2020 | Q2 2020 | % Change | Q3 2019 | % Change | |
| Adjusted EBITDA 1 | $(91.7) | $(155.7) | 41% | $(74.8) | -23% |
| Attributed as follows: | |||||
| - Operations and corporate overhead | $(44.4) | $(109.0) | 59% | $(52.8) | 16% |
| - Strategic investments and business development | $(39.1) | $(36.2) | -8% | $(8.9) | -339% |
| - Non-operating or under-utilized facilities | $(8.2) | $(10.5) | 22% | $(13.1) | 37% |
Gross margin percentage, before fair value
impacts in cost of sales, a non-IFRS measure, is a key operational metric that does not have any standardized meaning prescribed
by IFRS and may not be comparable to similar measures presented by other companies. This measure is calculated as net revenue
less inventory production costs expensed to cost of sales, divided by net revenue, and may be computed from the consolidated statements
of operations presented within this news release.
Adjusted EBITDA, a non-IFRS measure, is a key
operational metric that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures
presented by other companies. Adjusted EBITDA is calculated as earnings before interest, tax, depreciation and amortization, share-based
compensation expense, fair value changes and other non-cash items, and further adjusted to remove acquisition-related costs. The
Company attributes Adjusted EBITDA to its operations and corporate overhead, strategic investments and business developments, and
non-operating or under-utilized facilities. The Adjusted EBITDA reconciliation is presented within this news release and explained
in Management's Discussion & Analysis under "Adjusted EBITDA (Non-IFRS Measure)", a copy of which will be filed on
Free Cash Flow, a non-IFRS measure, is a key
operational metric that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures
presented by other companies. This measure is calculated as net cash provided by (used in) operating activities less purchases
and deposits of property, plant and equipment.
Transition to U.S. GAAP Reporting
As part of our U.S. financial reporting requirements,
Canopy Growth confirmed that, as of September 30, 2019, it no longer met the criteria for qualification as a foreign private issuer
because (1) more than 50% of the outstanding voting securities are held by residents of the United States, and (2) the majority
of Canopy Growth's directors are United States citizens.
Therefore, as of April 1, 2020 Canopy Growth
will be considered a United States domestic issuer and a large accelerated filer. As a result of this change, as of April 1, 2020,
Canopy Growth will be required to prepare its consolidated financial statements, including the Company's March 31, 2020 audited
annual consolidated financial statements, in conformity with United States generally accounting principles, with such change being
applied retrospectively. The extent of the impact of this change in accounting framework has not yet been quantified. Canopy Growth
will also be required to provide an auditor attestation report under Section 404(b) of the Sarbanes-Oxley Act.
This press release is intended to be read in
conjunction with the Company's Unaudited Condensed Interim Consolidated Financial Statements ("Financial Statements) and Management
Discussion & Analysis ("MD&A) for the three and nine months ended December 31, 2019, which will be filed on SEDAR